glp-1 news today september 2025 Medications Force Food Industry Rethink How Pharmacy Plans Are Managing
Description
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
One flat monthly price: $129/mo covers everything
The GLP-1 receptor agonist market is experiencing significant growth, driven by the increasing prevalence of type 2 diabetes and obesity, and the high...
Based on this review, evidence from head-to-head and insulin-comparator trials demonstrates that dual GIP/GLP-1 co-agonism consistently overcomes metabolic plateaus that result from single-pathway therapy, producing superior glycated hemoglobin reduction, bariatric-level weight loss (up to 25.3%), and robust macrovascular and heart failure protection, including a 38% reduction in composite cardiovascular risk among patients with heart failure with preserved ejection fraction (HFpEF)
Designed to complement your GLP-1 journey
However, renal effects of GLP-1 in heart failure (HF) has not been elucidated
